



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	☒ HIV-2 CDC310319 Virus
<b>Catalog Number:</b>	3930
<b>Lot Number:</b>	110068
<b>Release Category:</b>	C
<b>Provided:</b>	1.0 mL cell-free virus TCID <sub>50</sub> = 2.24 x 10 <sup>3</sup> /mL p27 antigen = 100 ng/mL.
<b>Original Source:</b>	Originally isolated from diagnostic culture of an Ivorian blood donor on PHA-stimulated normal human PBMCs. Stocks have been maintained on primary human PBMCs only.
<b>Host Strain:</b>	Primary PHA-stimulated human PBMCs are preferred host. Will also grow on PM-1, CEM, and MT-2.
<b>Propagation:</b>	Virus was propagated on PHA-stimulated (5 ug/ml) normal human PBMCs in RPMI 1640 (GIBCO) supplemented with 20 mM L-glutamine, 20% heat inactivated fetal calf serum (Hyclone), anti-human interferon (100 U/ml) and interleukin-2 (150 U/ml). Establish tissue culture infection with 100 ul of virus stock per 10 <sup>6</sup> PBMCs.
<b>Sterility:</b>	Negative for bacteria, fungi, and mycoplasma.
<b>Description:</b>	Primary isolate of HIV-2 subtype B propagated solely on primary human PBMCs; will form syncytia in MT-2 cells.
<b>Special Characteristics:</b>	Coreceptor usage described at <a href="http://hiv-web.lanl.gov/">http://hiv-web.lanl.gov/</a>
<b>Recommended Storage:</b>	Liquid nitrogen.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Contributor:** Original contributor is Dr. Stefan Wiktor, Director Projet Retro CI, Cote d'Ivoire. Isolation and viral stocks provided by Dr. Mark Rayfield, Centers for Disease Control and Prevention, Atlanta GA.

**References:** Owen SM, Ellenberger D, Rayfield M, Phillippe M, Hahn BH, Lal RB. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. *J Virol* **72**:5425-5432, 1998.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-2 CDC310319 Virus from Dr. Stefan Wiktor and Dr. Mark Rayfield."

**Scientist at for-profit institutions or who intend commercial use of this reagent must contact contact Dr. Mark Rayfield, Centers for Disease Control and Prevention, Tel:(404) 639-3820, Fax:(404) 639-4664, Email: [mark.rayfield@cdc.hhs.gov](mailto:mark.rayfield@cdc.hhs.gov), before the reagent can be released.**

**Last Updated:** August 02, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.